Not provided
Not provided
Not provided
Not provided
low recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective feasibility study to investigate Dilapan-S® as an outpatient method of cervical ripening in low risk pregnancies >=39 weeks.
In 2019, the ARRIVE trial was published, demonstrating that in low risk nulliparous women, induction of labor at 39 weeks was associated with a decreased risk for hypertensive disorders of pregnancy and decreased risk for cesarean without any increased risk for severe neonatal complications or perinatal death. (1) Based on the results of this trial, hospitals have been questioning the feasibility of implementing a protocol which offers induction of labor to low risk women at ≥39 weeks. There are concerns regarding the ability of a busy labor and delivery to accommodate women presenting for inductions with an unfavorable cervix. Outpatient mechanical cervical ripening would allow for women to start the process of induction of labor at home. This is appealing because cervical ripening is typically the longest component of the induction process. Mechanical cervical ripening is the process by which balloons or dilators are placed into the cervix.
There is lack of evidence on Dilapan-S® as an outpatient method of cervical ripening despite the potential benefits of increased maternal satisfaction and decreased length of hospital stay. With this in mind we propose a preliminary study of 40 women to assess for feasibility of performing a large randomized control trial and assess safety with outpatient treatment. This initial study is intended to assess the feasibility of outpatient cervical ripening, next day induction of labor, and safety. After completion of this feasibility study, the investigators plan to initiate a randomized control trial to assess the efficacy of outpatient Dilapan-S® for mechanical cervical ripening.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dilapan S | Other | Placement of dilators |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dilapan S | Device | Placement of Dilapan S |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time to delivery | Length of time between induction of labor start and delivery (hours) | from induction start to delivery, estimated average 12 hours |
| Measure | Description | Time Frame |
|---|---|---|
| APGAR score at 1and 5 min | APGAR score (number 0-10) | 1 and 5 minutes after birth |
| number of participants with maternal infection | chorioamnionitis, endometritis - Yes/No |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tara Lynch, MD | Albany Medical College | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Albany Medical Center | Albany | New York | 12208 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| during hospital admission, average 4 days |
| NICU admission | Neonatal admission to NICU (any admission) - Yes/No | through maternal hospital admission, average 4 days |
| Need for neonatal antibiotics | any antibiotic use in postnatal period (yes/no) | in the first 72 hours after delivery |
| Need for resipiratory support | any respiratory interventions after birth for neonate (composite of oxygen administration, respiratory distress syndrome, CPAP, intubation) (yes/No) | during hospital admission, average 4 days |
| mode of delivery | cesarean or vaginal (coded as cesarean delivery Y/N or vaginal delivery Y/N) | one time at the time of delivery, variable to occur during hospital admission, average 4 days |